A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)
A Multi-centre Prospective, Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus
Sponsor: Novo Nordisk A/S
Listed as NCT03374774, this observational or N/A phase trial focuses on Diabetes and Diabetes Mellitus, Type 2 and remains completed. Sponsored by Novo Nordisk A/S, it has been updated 9 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Sep 2018 — Jan 2021 [monthly]
Completed
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting
Status: Enrolling By Invitation → Active Not Recruiting
-
Apr 2018 — May 2018 [monthly]
Enrolling By Invitation
Phase: NA → None
-
Dec 2017 — Apr 2018 [monthly]
Enrolling By Invitation NA
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahmedabad, India , Bangalore, India , Belagavi, India , Coimbatore, India , Guwahati, India , Kalaburagi, India , Kolhāpur, India , Kolkata, India , Lucknow, India , Madurai, India and 5 more locations